RASSF1 - Wiki-MPM

Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
AURKB	aurora kinase B	Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 Separation of Sister Chromatids Resolution of Sister Chromatid Cohesion SUMOylation of DNA replication proteins RHO GTPases Activate Formins Regulation of TP53 Activity through Phosphorylation Mitotic Prometaphase Regulation of MECP2 expression and activity EML4 and NUDC in mitotic spindle formation	Hesperidin AT9283 Enzastaurin Reversine Fostamatinib TAK-901
BANF1	barrier to autointegration nuclear assembly factor 1	Integration of provirus 2-LTR circle formation Integration of viral DNA into host genomic DNA Autointegration results in viral DNA circles APOBEC3G mediated resistance to HIV-1 infection Vpr-mediated nuclear import of PICs Nuclear Envelope Breakdown Initiation of Nuclear Envelope (NE) Reformation
BRAF	B-Raf proto-oncogene, serine/threonine kinase	Spry regulation of FGF signaling Frs2-mediated activation Frs2-mediated activation ARMS-mediated activation Signalling to p38 via RIT and RIN RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants SHOC2 M1731 mutant abolishes MRAS complex function Gain-of-function MRAS complexes activate RAF signaling	Sorafenib XL281 RAF-265 PLX-4720 N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime Vemurafenib Regorafenib Dabrafenib Encorafenib Fostamatinib Ripretinib	Malignant melanoma Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Thyroid cancer
C7orf25	chromosome 7 open reading frame 25
C8orf33	chromosome 8 open reading frame 33
CCND2	cyclin D2	Cyclin D associated events in G1 Regulation of RUNX1 Expression and Activity Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) Drug-mediated inhibition of CDK4/CDK6 activity		Testicular cancer
CCNE1	cyclin E1	G0 and Early G1 SCF(Skp2)-mediated degradation of p27/p21 DNA Damage/Telomere Stress Induced Senescence Association of TriC/CCT with target proteins during biosynthesis TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest CDK-mediated phosphorylation and removal of Cdc6 Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes Cyclin E associated events during G1/S transition G1/S-Specific Transcription Cyclin D associated events in G1 p53-Dependent G1 DNA Damage Response PTK6 Regulates Cell Cycle Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) RHOBTB3 ATPase cycle		Laryngeal cancer Gastric cancer
CDC20	cell division cycle 20	Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components Inactivation of APC/C via direct inhibition of the APC/C complex Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal APC/C:Cdc20 mediated degradation of Cyclin B SCF-beta-TrCP mediated degradation of Emi1 APC/C:Cdc20 mediated degradation of Securin APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 Cdc20:Phospho-APC/C mediated degradation of Cyclin A Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase Regulation of APC/C activators between G1/S and early anaphase APC/C:Cdc20 mediated degradation of mitotic proteins Phosphorylation of Emi1 APC-Cdc20 mediated degradation of Nek2A Separation of Sister Chromatids Resolution of Sister Chromatid Cohesion RHO GTPases Activate Formins Ub-specific processing proteases Mitotic Prometaphase EML4 and NUDC in mitotic spindle formation Antigen processing: Ubiquitination & Proteasome degradation
CDK4	cyclin dependent kinase 4	SCF(Skp2)-mediated degradation of p27/p21 Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence RMTs methylate histone arginines Transcriptional regulation of white adipocyte differentiation Cyclin D associated events in G1 Ubiquitin-dependent degradation of Cyclin D Ubiquitin-dependent degradation of Cyclin D PTK6 Regulates Cell Cycle Transcriptional regulation by RUNX2 Meiotic recombination Transcriptional regulation of granulopoiesis Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) Drug-mediated inhibition of CDK4/CDK6 activity SPOP-mediated proteasomal degradation of PD-L1(CD274)	Purvalanol Alvocidib Palbociclib Ribociclib Abemaciclib Fostamatinib Trilaciclib	Malignant melanoma Glioma Cervical cancer
CDK6	cyclin dependent kinase 6	Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Cyclin D associated events in G1 Regulation of RUNX1 Expression and Activity Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) Drug-mediated inhibition of CDK4/CDK6 activity	Alvocidib (2S)-2-({6-[(3-Amino-5-chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-methyl-1-butanol Fisetin Palbociclib Ribociclib Abemaciclib Trilaciclib
CDKN2A	cyclin dependent kinase inhibitor 2A	Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Cyclin D associated events in G1 Transcriptional Regulation by VENTX Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Regulation of MITF-M-dependent genes involved in cell cycle and proliferation Apoptotic factor-mediated response Oxidative Stress Induced Senescence Oncogene Induced Senescence SUMOylation of DNA damage response and repair proteins SUMOylation of transcription factors Regulation of TP53 Degradation Stabilization of p53 Regulation of RUNX3 expression and activity Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function Evasion of Oncogene Induced Senescence Due to p14ARF Defects Evasion of Oxidative Stress Induced Senescence Due to p14ARF Defects Nuclear events mediated by NFE2L2		Chronic myeloid leukemia (CML) Non-small cell lung cancer Malignant islet cell carcinoma Adult T-cell leukemia Esophageal cancer Glioma Pancreatic cancer Nasopharyngeal cancer Hepatocellular carcinoma Squamous cell carcinoma Penile cancer Oral cancer Malignant melanoma Burkitt lymphoma Gallbladder cancer Bladder cancer Laryngeal cancer Cholangiocarcinoma Malignant pleural mesothelioma Osteosarcoma Type II diabetes mellitus
CDKN2B	cyclin dependent kinase inhibitor 2B	SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Cyclin D associated events in G1		Type II diabetes mellitus Osteosarcoma Malignant pleural mesothelioma
CLNK	cytokine dependent hematopoietic cell linker
CNKSR1	connector enhancer of kinase suppressor of Ras 1	MAP2K and MAPK activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants
DAXX	death domain associated protein	SUMOylation of transcription cofactors Regulation of TP53 Degradation HCMV Early Events Inhibition of DNA recombination at telomere Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations
DDB1	damage specific DNA binding protein 1	Recognition of DNA damage by PCNA-containing replication complex DNA Damage Recognition in GG-NER Formation of Incision Complex in GG-NER Dual Incision in GG-NER Formation of TC-NER Pre-Incision Complex Transcription-Coupled Nucleotide Excision Repair (TC-NER) Dual incision in TC-NER Gap-filling DNA repair synthesis and ligation in TC-NER Neddylation		Disorders of nucleotide excision repair, including: Xeroderma pigmentosum (XP); Cockayne syndrome (CS); UV-sensitive syndrome (UVS); Trichothiodystrophy (TTD); Cerebro-oculo-facio-skeletal syndrome (COFS); XFE progeroid syndrome
E4F1	E4F transcription factor 1
EPHA2	EPH receptor A2	EPH-Ephrin signaling EPH-Ephrin signaling EPHA-mediated growth cone collapse EPHA-mediated growth cone collapse EPH-ephrin mediated repulsion of cells EPH-ephrin mediated repulsion of cells RAC1 GTPase cycle RAC2 GTPase cycle RHOG GTPase cycle RHOU GTPase cycle RAC3 GTPase cycle RHOV GTPase cycle RND3 GTPase cycle RND2 GTPase cycle RND1 GTPase cycle	Dasatinib Phosphoaminophosphonic Acid-Adenylate Ester Regorafenib Fostamatinib
ERBB2	erb-b2 receptor tyrosine kinase 2	Signaling by ERBB2 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling GRB7 events in ERBB2 signaling Downregulation of ERBB2:ERBB3 signaling GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Constitutive Signaling by Aberrant PI3K in Cancer Sema4D induced cell migration and growth-cone collapse RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Constitutive Signaling by Overexpressed ERBB2 Drug-mediated inhibition of ERBB2 signaling Signaling by ERBB2 KD Mutants Resistance of ERBB2 KD mutants to trastuzumab Resistance of ERBB2 KD mutants to sapitinib Resistance of ERBB2 KD mutants to tesevatinib Resistance of ERBB2 KD mutants to neratinib Resistance of ERBB2 KD mutants to osimertinib Resistance of ERBB2 KD mutants to afatinib Resistance of ERBB2 KD mutants to AEE788 Resistance of ERBB2 KD mutants to lapatinib Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Drug resistance in ERBB2 TMD/JMD mutants Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Myoepithelial Cells Developmental Lineage of Mammary Stem Cells	Trastuzumab Lapatinib IGN311 Trastuzumab emtansine Varlitinib AV-412 Pertuzumab Afatinib Tucatinib Tesevatinib Fostamatinib Brigatinib Margetuximab Zanubrutinib	Breast cancer Cervical cancer Cholangiocarcinoma Pancreatic cancer Gastric cancer Ovarian cancer Choriocarcinoma Endometrial Cancer Bladder cancer
EXOSC8	exosome component 8	ATF4 activates genes in response to endoplasmic reticulum stress mRNA decay by 3' to 5' exoribonuclease Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA KSRP (KHSRP) binds and destabilizes mRNA Major pathway of rRNA processing in the nucleolus and cytosol Nuclear RNA decay

Search Results for: RASSF1